These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 35191358)
21. Voxelotor for the treatment of sickle cell disease. Vissa M; Vichinsky E Expert Rev Hematol; 2021 Mar; 14(3):253-262. PubMed ID: 33602029 [No Abstract] [Full Text] [Related]
22. Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease. Lemon N; Sterk E; Rech MA Am J Emerg Med; 2022 May; 55():225.e1-225.e3. PubMed ID: 34991907 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease. Hutchaleelaha A; Patel M; Washington C; Siu V; Allen E; Oksenberg D; Gretler DD; Mant T; Lehrer-Graiwer J Br J Clin Pharmacol; 2019 Jun; 85(6):1290-1302. PubMed ID: 30743314 [TBL] [Abstract][Full Text] [Related]
24. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia. Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381 [TBL] [Abstract][Full Text] [Related]
25. Accelerated approval of Oxbryta® (voxelotor): A case study on novel endpoint selection in sickle cell disease. Lehrer-Graiwer J; Yokoshima L; Tong B; Love TW Contemp Clin Trials; 2020 Nov; 98():106161. PubMed ID: 33010428 [TBL] [Abstract][Full Text] [Related]
26. Model-informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma. Savic RM; Green ML; Jorga K; Zager M; Washington CB CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):687-697. PubMed ID: 35447014 [TBL] [Abstract][Full Text] [Related]
27. Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease. Alshurafa A; Yassin MA Front Med (Lausanne); 2022; 9():931924. PubMed ID: 36186817 [TBL] [Abstract][Full Text] [Related]
28. Real-world data on voxelotor to treat patients with sickle cell disease. Muschick K; Fuqua T; Stoker-Postier C; Anderson AR Eur J Haematol; 2022 Aug; 109(2):154-161. PubMed ID: 35460521 [TBL] [Abstract][Full Text] [Related]
29. How do we monitor hemoglobin S in patients who undergo red blood cell exchange and take voxelotor? Godbey EA; Anderson MR; M Bachmann L; Sanford KW; Wieditz K; Roseff SD Transfusion; 2021 Jun; 61(6):1680-1683. PubMed ID: 33880770 [No Abstract] [Full Text] [Related]
30. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review. Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735 [TBL] [Abstract][Full Text] [Related]
31. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin. Enakaya NA; Jefferson A; Chew-Martinez D; Matthews JS Acc Chem Res; 2023 Jun; 56(11):1279-1286. PubMed ID: 36946781 [TBL] [Abstract][Full Text] [Related]
32. The efficacy of voxelotor, 900 mg in patients with sickle cell anaemia: A meta-analysis of the randomised controlled trials. Tanriverdi LH; Sarici A; Erkurt MA; Parlakpinar H Int J Clin Pract; 2021 Jun; 75(6):e13967. PubMed ID: 33369007 [TBL] [Abstract][Full Text] [Related]
33. Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview Study. Brown C; Idowu M; Drachtman R; Beaubrun A; Agodoa I; Nguyen A; Lipman K; Moshkovich O; Murphy R; Bellenger MA; Smith W Biomed Res Int; 2023; 2023():7533111. PubMed ID: 36748060 [TBL] [Abstract][Full Text] [Related]
34. Structure-based computational design of novel covalent binders for the treatment of sickle cell disease. Ogunlana AT; Boyenle ID; Ojo TO; Quadri BO; Elegbeleye OE; Ogbonna HN; Ayoola SO; Badmus IO; Manica AK; Joshua KI; Onikute OW; Anamelechi JP; Odetunde A; Falusi AG; Oyedele AK J Mol Graph Model; 2023 Nov; 124():108549. PubMed ID: 37339569 [TBL] [Abstract][Full Text] [Related]